Companies are now able to register R&D activities conducted during the year ended 30 June 2022 (FY22) with AusIndustry. For the FY22 period, the application process is again administered through the new online customer portal which was introduced for the prior FY21 period. There were substantial changes made to the R&D activity technical description requirements in FY21, however the AusIndustry activity disclosure requirements for FY22 appear not to have materially changed. The big changes for FY22 R&D c laims relate […]
As previously reported, Real Energy Ltd was involved in a dispute with R&D Tax Incentive programme regulators over the eligibility of its R&D activities spanning a number of years. Corporate activity between Real Energy and Strata-X has since merged to form Pure Hydrogen Corporation Ltd. Pure Hydrogen Corporation on the 23rd of June provided the following update on the dispute: The matter was taken to the Administrative Appeals Tribunal over 3 years ago and now the parties have consented to […]
The QLD government has announced that round 9 of the Ignite Ideas funding is available to commercialise highly innovative and new products or services that are at minimum viable product stage or beyond. The Ignite Ideas Fund is designed to support Queensland based small to medium businesses that have high-growth potential to undertake commercialisation projects that will: Strengthen key industries in Queensland. Diversify the Queensland economy. Compete in domestic and global markets. Engage and/or benefit regional Queensland. Create new jobs, now […]
Melbourne based Paradigm Biopharmaceuticals has reported receipt of a $8.2 million research and development tax incentive refund for the YE 30 June 2021 relating to ongoing R&D activities into its pentosan polysulfate sodium treatment. The company has advised that the funds will be reinvested in R&D activities and to support its global Phase 3 and Phase 2 clinical programs. Paradigm Biopharmaceuticals’ R&D offset refund is one of the larger R&D tax offsets reported, alongside the likes of Telix Pharmaceuticals’ R&D […]